Screener
Amylyx Pharmaceuticals, Inc. AMLX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Amylyx Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s debt-to-equity?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported debt-to-equity of 0× in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s debt-to-equity decreased by 38.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s debt-to-equity?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s debt-to-equity has grown at a 2.0% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude